

Attorney Docket NO. I/2000.552 US

REMARKS

The pending claims of the instant application are 15-47. Applicants have canceled withdrawn claims 25-34 without prejudice to the subject matter contained therein. Applicants preserve the right to file a Divisional Application directed to the withdrawn claims. Applicants have amended claims 16, 45, 46 and 47 to correct typographical errors and correct grammar. The Examiner has examined claims 15-24 and 35-47.

Applicants have amended the specification to assign SEQ ID NO to nucleotides sequences having 10 or more nucleotides.

Issue Concerning Sequence Compliance

After discussing this matter with the Examiner by telephone, Applicants have amended the specification on pages 9, 11 and 12 by inserting SEQ ID NO to nucleotide sequences with over 10 nucleotides.

Applicants assert that the specification is now in compliance with the sequence rules. Applicants respectfully request withdrawal of the objection.

Issue Under 35 U.S.C. §112

Claim 16 stands rejected under 35 U.S.C. §112, second paragraph, as being allegedly indefinite. The Examiner has identified a typographical error in claim 16.

Applicants have amended claim 16 to correct the

Attorney Docket NO. I/2000.552 US

typographical error.

Applicants respectfully request withdrawal of the 35 U.S.C. §112, second paragraph rejection.

Allowable Subject Matter

The Examiner has indicated that claims 15, 17-24 and 35-47 are in condition for allowance. Applicants wish to thank the Examiner for this communication. Applicants have addressed the rejection to claim 16 and the objection to the specification; therefore, the application should be in condition for allowance.

Conclusion

All the stated grounds of the rejections have been properly traversed, accommodated or rendered moot. Applicants respectfully submit that the present application is in condition for allowance.


If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (302) 934-4395, in Millsboro, Delaware.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334 for any additional

Attorney Docket NO. I/2000.552 US

fees required under 37 C.F.R. \$1.16 or under 37 C.F.R. \$1.17;
particularly extension of time fees.

Respectfully submitted,


Mark W. Milstead
Patent Counsel
Registration No. 45,825

Attorney Docket NO. I/2000.552 US

Akzo Nobel Pharma
Patent Department
405 State Street
P.O. Box 318
Millsboro, DE 19966
Tel: (302) 934-4395
Fax: (302) 934-4305

MWM